Additional file 1 of Mesenchymal stromal cells for the prophylaxis and treatment of graft-versus-host disease—a meta-analysis
Creators: name: Morata-Tarifa, Cynthia
name: Macías-Sánchez, María Del Mar
name: Gutiérrez-Pizarraya, Antonio
name: Sanchez-Pernaute, Rosario
Publisher: name: figshare
Year: 2020
Subjects: subject: Space Science
subject: Medicine
subject: Cell Biology
subject: Pharmacology
subject: Biotechnology
subject: 59999 Environmental Sciences not elsewhere classified
subject: FOS: Earth and related environmental sciences
subject: FOS: Earth and related environmental sciences
subject: Ecology
subject: FOS: Biological sciences
subject: FOS: Biological sciences
subject: Immunology
subject: FOS: Clinical medicine
subject: FOS: Clinical medicine
subject: 69999 Biological Sciences not elsewhere classified
subject: Developmental Biology
subject: 110309 Infectious Diseases
subject: FOS: Health sciences
subject: FOS: Health sciences
subject: Computational Biology

description: Additional file 1: Figure S1. Risk of Bias. Figure S2. Overall survival of MSC and control patients. Figure S3. Overall survival at last follow-up. Figure S4. aGvHD incidence for patients from the MSC group compared to control patients. Figure S5. aGvHD (grade III-IV) incidence for patients from the MSC group compared to control patients. Figure S6. Outcome and MSC doses of patients infused for prophylaxis. Figure S7. Risk of Bias. Figure S8. Overall survival of patients with aGvHD at last follow-up. Figure S9. Grade-specific overall survival of patients with aGvHD from the MSC group at last follow-up. Figure S10. Overall survival of patients with aGvHD from the MSC group regarding to the number of organ affected. Figure S11. Organ-specific overall survival of patients with aGvHD from the MSC group at last follow-up. Figure S12. Overall survival of aGvHD patients with multiorgan affection from the MSC group at last follow-up. Figure S13. Overall survival and first day of infusion of MSC from HSCT of patients with aGvHD. Figure S14. Overall and complete responses of patients with aGvHD from the MSC group. Figure S15. Grade-specific overall response of patients with aGvHD from the MSC group at last follow-up. Figure S16. Overall response of patients with aGvHD from the MSC group regarding to the number of organs affected. Figure S17. Complete response of patients with aGvHD from the MSC group regarding to the number of organ affected. Figure S18. Complete response of patients with aGvHD grade II vs grade III-IV. Figure S19. Organ-specific overall and complete responses of patients with aGvHD from the MSC group. Figure S20. Gut-specific overall response of patients with aGvHD from the MSC group. Figure S21. Correlation between responder rates and MSC dose or time from HSCT. Figure S22. Outome of aGvHD vs cGvHD patients. Table S1. Detailed search strategy. Table S2. Characteristics of the included studies that evaluated the use of MSC for GvHD prophylaxis. Table S3. Characteristics of the included studies using MSC for the treatment of aGvHD and/or cGvHD. Table S4. Characteristics of the control group for included studies using MSC for the treatment of GvHD. Table S5. Number of patients with aGvHD infused with MSC divided by grade and organs involved. Table S6. Subgroup analysis for the overall survival of patients with aGvHD infused with MSC at last follow-up. Table S7. Subgroup analysis for the overall response of patients with aGvHD infused with MSC. Table S8. Subgroup analysis for the complete response of patients with aGvHD infused with MSC.